Información de la revista
Vol. 115. Núm. 1.
Páginas 106-109 (Enero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 115. Núm. 1.
Páginas 106-109 (Enero 2024)
Case and Research Letter
Acceso a texto completo
Clinical Features, Epidemiology, Management and Prognosis of Patients With Primary Cutaneous Marginal Zone Lymphoma: An Observational Study
Características clínicas, epidemiología, manejo y pronóstico de los pacientes con linfoma cutáneo de la zona marginal primario: estudio observacional
Visitas
1973
P.J. Gómez Ariasa,
Autor para correspondencia
pedrojesusgomezarias@gmail.com

Corresponding author.
, S. Vázquez Díazb, C. Rothenberg Lausellc, A. Sanz Zorrillad, B. Baleato Gómeza
a Dermatology & Venereology Department, Reina Sofía Universitary Hospital, Córdoba, Spain
b Hematology & Hemotherapy Department, Juan Ramón Jiménez Universitary Hospital, Huelva, Spain
c Medical Science Campus, University of Puerto Rico, Puerto Rico, USA
d Pathologist Pathology Department, Reina Sofía Universitary Hospital, Córdoba, Spain
Contenido relaccionado
P.J. Gómez Arias, S. Vázquez Díaz, C. Rothenberg Lausell, A. Sanz Zorrilla, B. Baleato Gómez
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (2)
Table 1. Resume of clinical characteristics, response to treatment and outcomes.
Table 2. Results provided by other PCMZL case series.
Mostrar másMostrar menos
Texto completo
To the Editor:

Primary cutaneous marginal zone lymphoma (PCMZL) is a low-grade B cell primary skin lymphoma,1 usually found in male adults around 50–55 years old.2,3 This disease can present as single or multiple erythematous macules, plaques, or tumors. The most common locations are the trunk and upper limbs.4 Treatment of this disease is based on only a limited number of short case series, and well-designed clinical trials are lacking; therefore, strong evidence is scarce. Currently, solitary lesions are treated via surgery or local radiotherapy, whereas multiple lesions are treated with radiotherapy, intravenous administration of rituximab, or watchful follow-up.5 The prognosis of this type of lymphoma is excellent, with a five-year survival rate of 95–100%.4 Nevertheless, PCMZL skin relapses are common (44–50%).6 This study aims to describe the epidemiology and outcome of patients with PCMZL in a hospital with rare skin lymphoma management expertise.

This observational, longitudinal, retrospective study included all patients histologically diagnosed as PCMZL at our institution from January 2007 to December 2020. Clinical data were collected, processed, and analyzed using SPSS v.25 statistical software.

Ultimately, 24 patients were evaluated during the study period, of which 62.5% (n=15) were men, and the median age was 58. A solitary nodule (75%, n=18) was the most frequent presentation of PCMZL, followed by multiple nodules (16.2%, n=4). These lesions were localized more frequently in the head and neck area (33.3%, n=8), upper limbs (33.3%, n=8), and trunk (25%, n=6). In all patients, the results of whole-body computed tomography (CT) showed no extracutaneous involvement. T1A was the most common EORT/ISCL stage (79.2%, n=19). Local radiotherapy of the lesion and the surrounding skin (1cm) using electron beam irradiation (30Gy) was the most common treatment applied (n=11, 45.8%), followed by a wide margin (1–1.5cm) surgical excision (n=5, 20.8%). A complete response was achieved in 17 patients (70.8%), while seven patients (29.2%) showed a partial response with disease stabilization. Among patients with a complete response to treatment, seven (29.2%) experienced a disease relapse. For these seven patients, the primary treatment was radiotherapy (n=4), surgical excision (n=2), and surgical excision followed by radiotherapy (n=1). In five of these patients, the recurrence was found at the same site as the primary lesion (see Table 1 for a short resume of clinical characteristics, response to treatment, and outcomes).

Table 1.

Resume of clinical characteristics, response to treatment and outcomes.

  n 
Patients  24   
Average age (years)  54   
Sex
Female  37.5% 
Male  15  62.5% 
Location
Head and neck  33.3% 
Upper limb  33.3% 
Trunk  25% 
Various locations  8.3% 
Presentation
Single tumors  18  75% 
Multiple tumors  16.7% 
Single plaque  4.2% 
Plaque and tumos  4.2% 
Stage EORT/ISCL
T1a  19  79.2% 
T2a  12.5% 
T3a  4.2% 
T3b  4.2% 
Treatment
Local electron beam irradiation  11  45.8% 
Wide margin surgical excision  20.83% 
Excision+radiotherapy  12.5% 
Endovenous rituximab  8.3% 
Watchful follow-up  8.3% 
Endovenous rituximab and low dose methotrexate  4.2% 
Response to first treatment
Complete response  17  70.8% 
Partial response  29.2% 
Recurrence (among patients with CR)
Yes  29.2% 
No  10  41.6% 
Recurrence status post treatment
Local electron beam irradiation  4/11  36.3% 
Wide margin surgical excision  2/5  40% 
Excision+radiotherapy  1/3  33.3% 
Others  0/5  – 
Treatment of recurrence
Watchful follow-up  28.5% 
Surgical wide margin exeresis  28.5% 
Endovenous rituximab  14.2% 
Local electron beam irradiation  14.2% 
Low dose endovenous chlorambucil  14.2% 
Mean DFI (months)  19   
Mean follow-up period (months)  41   
Death
Yes  0% 
No  24  100% 
Extracutaneous spread
Yes  0% 
No  24  100% 

CR: complete response; DFI: disease free interval.

The median disease-free interval of patients who suffered a relapse was 19 months. All recurrences occurred within the first three years of follow-up. The mean follow-up period in our series was 42 months (median 31 months). None of the patients experienced nodal relapse or visceral or bone marrow involvement during the follow-up period. No deaths caused by PCMZL were reported. At the end of the study, the percentage of disease-free patients was 54.1% (n=13).

Our experience with patients with PCLZM in our hospital is similar to other centers; lesions are more common in 50–60-year-old men with a relatively high recurrence rate but an excellent survival rate. Primary staging in patients with PCMZL should include a physical examination, laboratory tests with a complete blood count and lactate dehydrogenase levels, skin biopsy, and complete body CT or FDG-PET scan. A bone marrow biopsy is not indicated for PCMZL.5

Concerning treatment for localized lesions, local electron radiotherapy (20–35Gy and 1–1.5cm margin)7 or wide margin excision are indicated as the first-choice treatments.5 Some authors found no difference in recurrence rates between the two treatment groups, while others showed a higher relapse rate with excised lesions, although this difference was not statistically significant.6 In other studies, recurrence was found in non-irradiated areas.8 For multifocal disease, low-dose local radiotherapy, intralesional corticosteroids, intravenous or intralesional3 rituximab, or a watchful follow-up period are the most commonly applied treatments.5 Intravenous and intralesional rituximab achieved a complete response in most cases, but relapses after suspension may occur.9 Due to the scarcity of patients included in our case series, it was not possible to make statistical inferences by comparing the different treatments applied, which is a limitation of our study. The relapse rate ranged from 36%10 to 60%.8 Relapses seem more common in multifocal disease (T3 EORTC stage) but have also been described in the T1–T2 stages.6

The spread of PCMZL in other organs was uncommon during follow-up (4–6.2%).6,11 The prognosis of patients with PCMZL is excellent, with a 5-year survival rate of >90% (93% and 95%).6,8 An extended follow-up period for patients with PCLZM, sometimes as long as five years after a complete response to a primary treatment, is recommended due to possible late relapse6 (see Table 2 for a relation of the results provided by other PCMZL case series). The optimal management of these patients requires a multidisciplinary approach. Multicentric studies and clinical trials are needed to assess the best therapeutic approach and management of patients with PCMZL.

Table 2.

Results provided by other PCMZL case series.

Article  n  Treatment applied  Complete response rate after first treatment  Recurrence rate  Free of disease interval  Site of recurrence  Other findings 
Servitje et al.6  137 (51%: T1, T2 29%, T3 20%)  Surgery 44%, radiotherapy 37%, surgery+radiotherapy 5%, other 12%  88%  44%  47 months  4% extracutaneous involvement during follow-up1 death due to PCMZL  Survival rate after 10 years, 93%.No differences between surgery and radiotherapy.RecurrenceLate recurrence – after 5 years of follow up-were seen. 
Senff et al.8  153 (44% mutlifocal, 36% multifocal, 20% localized)  Radiotherapy (in most patients: electron beam irradiation 4–10MeV)  100%  60%  16 months  Recurrence was always found in no irradiated areas  Disease specific survival rate 95%. 
Zinzani et al.10  151 (58.3% single lesion)  Radiotherapy (83), surgery (39), chemotherapy (29)  95.4%  44.4%  –  6.2% extracutaneous involvement  No differences between surgery and radiotherapy in recurrence rate.Overall survival after 10 years of follow-up: 90.5% 
Hamilton et al.9  59 (100% IAE stage)  83% radiotherapy (electron beam 25–35Gy), 12% surgery  95%  36%  –  74% skin, 11% lymph nodes, 15% other locations  – 
Conflict of interests

The authors declare that they have no conflict of interest.

References
[1]
R. Willemze, E.S. Jaffe, G. Burg, L. Cerroni, E. Berti, S.H. Swerdlow, et al.
WHO-EORTC classification for cutaneous lymphomas.
Blood, 105 (2005), pp. 3768-3785
[2]
J.J. Hoefnagel, M.H. Vermeer, P.M. Jansen, F. Heule, P.C. van Voorst Vader, C.J.G. Sanders, et al.
Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases.
Arch Dermatol, 141 (2005), pp. 1139-1145
[3]
A.L. Suárez, M. Pulitzer, S. Horwitz, A. Moskowitz, C. Querfeld, P.L. Myskowski.
Primary cutaneous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification.
J Am Acad Dermatol, 69 (2013), pp. 329
[4]
J. Farhadian, V. Terushkin, S.A. Meehan, J.-A. Latkowski.
Primary cutaneous marginal-zone lymphoma.
Dermatol Online J, 22 (2016), pp. 12
[5]
R. Willemze, E. Hodak, P.L. Zinzani, L. Specht, M. Ladetto, ESMO Guidelines Committee.
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol, 29 (2018), pp. iv30-iv40
[6]
O. Servitje, C. Muniesa, Y. Benavente, V. Monsálvez, M.P. Garcia-Muret, F. Gallardo, et al.
Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
J Am Acad Dermatol, 69 (2013), pp. 357-365
[7]
L. Specht, B. Dabaja, T. Illidge, L.D. Wilson, R.T. Hoppe.
Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.
Int J Radiat Oncol Biol Phys, 92 (2015), pp. 32-39
[8]
N.J. Senff, J.J. Hoefnagel, K.J. Neelis, M.H. Vermeer, E.M. Noordijk, R. Willemze, et al.
Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
Arch Dermatol, 143 (2007), pp. 1520-1526
[9]
Y. Peñate, B. Hernández-Machín, L.I. Pérez-Méndez, F. Santiago, B. Rosales, O. Servitje, et al.
Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicenter study; the Spanish Working Group on Cutaneous Lymphoma.
Br J Dermatol, 167 (2012), pp. 174-179
[10]
S.N. Hamilton, E.S. Wai, K. Tan, C. Alexander, R.D. Gascoyne, J.M. Connors.
Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC cancer agency experience.
Radiat Oncol Biol, 87 (2021), pp. 719-725
[11]
P.L. Zinzani, P. Quaglino, N. Pimpinelli, E. Berti, G. Baliva, S. Rupoli, et al.
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.
J Clin Oncol, 24 (2006), pp. 1376-1382
Copyright © 2023. AEDV
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?